Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency

Abstract Background Renal insufficiency is one of the most common complications in the treatment of multiple myeloma (MM). The administration of isatuximab showed improved patient outcome regarding the occurrence of renal insufficiency. Building on the results of the ICARIA-MM study, the aim of this...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	F. Jakobs, P. Ahmadi, V. Osterkamp, J. Jeck, U. Holtick, C. Scheid, Florian Kron
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BMC 2025-03-01
Σειρά:	Cost Effectiveness and Resource Allocation
Θέματα:	Multiple myeloma Renal insufficiency Cost savings Isatuximab Hospital management
Διαθέσιμο Online:	https://doi.org/10.1186/s12962-024-00600-w
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!